ART Receives $500,000 From Government of Canada to Pursue Commercialization Activities in North America
ART's two lead products-SoftScan and Optix-are based on a technology that uses light to measure physiological changes in living tissue, indicating the presence of anomalies, tumours, or lesions. In clinical settings, the SoftScan system for breast imaging is demonstrating its importance as a valuable tool for clinicians in the diagnosis and treatment monitoring of breast cancer. Oncologists are able to see rapidly if a course of treatment is working and then adjust or interrupt treatment. ART's other key imaging device, the Optix molecular imaging system, is designed to visualize and characterize molecular events in small animals at the preclinical study phases of new drugs. A pre-commercial launch of the new generation of the system, called Optix MX3, was held last May in Europe.
Most read news
Organizations
Other news from the department business & finance
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.